New pricing rules lower access barriers for orphan drugs in France
A new “flat-rate payment” system may likely be very common for upcoming orphan medicines in France.
By
A new “flat-rate payment” system may likely be very common for upcoming orphan medicines in France.
ByICER's assessment is extremely unusual, since only 10% of reviewed drugs fell within ICER's cost-effectiveness threshold, as per a GlobalData…
ByA recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
BySeveral reasons specified in the ODAC rejection are specific to the sintilimab BLA.
ByUkraine's health minister Viktor Lyashko pushes for 'business as usual' as Russia invades, but ingenuity and support are needed.
ByAduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the…
ByAs we start 2022, the global market access environment has reached an unprecedented high level of risk.
ByThere may be ways to introduce price control under federal drug programmes by stealth in the absence of state price…
ByThank you for subscribing to Pharmaceutical Technology